Randomised controlled trial. Comparison of iNfliximab and ciclosporin in STeroid Resistant Ulcerative Colitis: Trial design and protocol (CONSTRUCT)

BMJ Open

Volumn 4, Issue 4, 2014, Pages

  Seagrove, Anne C ^a   Alam, M Fasihul ^b   Alrubaiy, Laith ^a   Cheung, Wai Yee ^a   Clement, Clare ^a   Cohen, David ^b   Grey, Michelle ^a   Hilton, Mike ^a   Hutchings, Hayley ^a   Morgan, Jayne ^a   Rapport, Frances ^a   Roberts, Stephen E ^a   Russell, Daphne ^a   Russell, Ian ^a   Thomas, Linzi ^c   Thorne, Kymberley ^a   Watkins, Alan ^a   Williams, John G ^a  

^a SWANSEA UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF GLAMORGAN   (United Kingdom)

^c SINGLETON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; COTRIMOXAZOLE; CYCLOSPORIN A; INFLIXIMAB; MERCAPTOPURINE; STEROID; CORTICOSTEROID; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

ABSCESS; ACUTE DISEASE; ADULT; ARTICLE; BACTERIAL INFECTION; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; COLON RESECTION; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; CROHN AND COLITIS QUESTIONNAIRE; DISEASE ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG TREATMENT FAILURE; EMERGENCY SURGERY; EQ 5D; FOLLOW UP; HEALTH CARE COST; HEALTH PERSONNEL ATTITUDE; HOSPITAL ADMISSION; HOSPITAL READMISSION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION PREVENTION; INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE; INTERVIEW; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; MORBIDITY; MORTALITY; MULTICENTER STUDY (TOPIC); NATIONAL HEALTH SERVICE; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESEARCH ETHICS; SHORT FORM 12; STUDY DESIGN; SURVIVAL; TREATMENT RESPONSE; ULCERATIVE COLITIS; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT; YOUNG ADULT; CLINICAL TRIAL; COLITIS, ULCERATIVE; COST BENEFIT ANALYSIS; DISEASE COURSE; DRUG COST; DRUG RESISTANCE; ECONOMICS; GREAT BRITAIN; MULTICENTER STUDY; PATHOPHYSIOLOGY;

ADRENAL CORTEX HORMONES; COLECTOMY; COLITIS, ULCERATIVE; COST-BENEFIT ANALYSIS; CYCLOSPORINE; DISEASE PROGRESSION; DRUG COSTS; DRUG RESISTANCE; GREAT BRITAIN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLIXIMAB; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS;

EID: 84899736293     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-005091     Document Type: Article

References (49)

1. Rubin GP, Hungin AP, Kelly PJ, et al. Inflammatory bowel disease: epidemiology and management in an English general practice population. Aliment Pharmacol Ther 2000;14:1553-9. (Pubitemid 32011728)
2. Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004;53(Suppl 5):V1-16.
3. Roberts SE, Williams JG, Yeates D, et al. Mortality in patients with and without colectomy admitted to hospital for ulcerative colitis and Crohn's disease: record linkage studies. BMJ 2007;335:1033-6. (Pubitemid 350157263)
4. Ochsenkuhn T, Sackmann M, Goke B. Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study. Eur J Gastroenterol Hepatol 2004;16:1167-71. (Pubitemid 39488789)
5. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76. (Pubitemid 41770166)
6. Aberra FN, Lichtenstein GR. Infliximab in ulcerative colitis. Gastroenterol Clin North Am 2006;35:821-36. (Pubitemid 44791836)
7. Gisbert JP, Gonzalez-Lama Y, Mate J. Systematic review: Infliximab therapy in ulcerative colitis. Aliment Pharmacol Ther 2007;25:19-37. (Pubitemid 44902861)
8. Feagan BG, Reinisch W, Rutgeerts P, et al. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol 2007;102:794-802. (Pubitemid 46496629)
9. National Institute for Health and Care Excellence. Ulcerative colitis (acute exacerbations) - infliximab (TA163) 2008. http://ww.nice.org.uk/TA163 (accessed 14 Mar 2014).
10. Naftali T, Novis B, Pomeranz I, et al. Cyclosporin for severe ulcerative colitis. Isr Med Assoc J 2000;2:588-91.
11. Hawthorne AB. Ciclosporin and refractory colitis. Eur J Gastroenterol Hepatol 2003;15:239-44. (Pubitemid 36337842)
12. Message L, Bourreille A, Laharie D, et al. Efficacy of intravenous cyclosporin in moderately severe ulcerative colitis refractory to steroids. Gastroenterol Clin Biol 2005;29:231-5. (Pubitemid 40516308)
13. Haslam N, Hearing SD, Probert CS. Audit of cyclosporin use in inflammatory bowel disease: limited benefits, numerous side-effects. Eur J Gastroenterol Hepatol 2000;12:657-60. (Pubitemid 30433543)
14. Van Assche G, D'Haens G, Noman M, et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003;125:1025-31. (Pubitemid 37193449)
15. Creed TJ, Probert CS. Review article: steroid resistance in inflammatory bowel disease-mechanisms and therapeutic strategies. Aliment Pharmacol Ther 2007;25:111-22. (Pubitemid 46046368)
16. Turner D, Walsh CM, Steinhart AH, et al. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol 2007;5:103-10. (Pubitemid 46096828)
17. Shibolet O, Regushevskaya E, Brezis M, et al. Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst Rev 2005;(1):CD004277.
18. Chang KH, Burke JP, Coffey JC. Infliximab versus cyclosporine as rescue therapy in acute severe steroid-refractory ulcerative colitis: a systematic review and meta-analysis. Int J Colorectal Dis 2013;28:287-93.
19. Dean KE, Hikaka J, Huakau JT, et al . Infliximab or cyclosporine for acute severe ulcerative colitis: a retrospective analysis. J Gastroenterol Hepatol 2012;27:487-92.
20. Laharie D, Bourreille A, Branche J, et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 2012;380:1909-15.
21. Bryan S, Andronis L, Hyde C, et al. Infliximab for the treatment of acute exacerbations of ulcerative colitis. Health Technol Assess 2010;14;Suppl 1/02
22. Schwartz D, Lellouch D. Explanatory and pragmatic attitudes in therapeutic trials. J Chronic Dis 1967;20:637-48.
23. Ford DV, Jones KH, Verplancke JP, et al. The SAIL Databank: building a national architecture for e-health research and evaluation. BMC Health Serv Res 2009;9:157.
24. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. BMJ 1955;2:1041-8.
25. Russell IT, Edwards RT, Gliddon AE, et al. Cancer of the oesophagous or gastricus: new assessment of the technology of endosonography (COGNATE). Health Technol Assess 2013;17:1-170
26. Russell IT, Bedson E, Bell D, et al. Folate Augmentation of Treatment-Evaluation of Depression (FolATED): a randomised controlled trial. Health Technology Assessment 2014;18 (in press).
27. Evans BA, Bedson E, Bell P, et al. Involving service users in trials: developing a standard operating procedure. Trials 2013;14:219.
28. Russell D, Hoare ZS, Whitaker R, et al. Generalized method for adaptive randomization in clinical trials. Stat Med 2011;30:922-34.
29. Cheung WY, Garratt AM, Russell IT, et al. The UK IBDQ-a British version of the inflammatory bowel disease questionnaire. Development and validation. J Clin Epidemiol 2000;53:297-306. (Pubitemid 30173250)
30. Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996;34:220-33. (Pubitemid 126433231)
31. Brooks R, Rabin R, de Charro F. The measurement and valuation of health status using EQ-5D: A European perspective: evidence from the EuroQol BIO MED Research Programme. Springer, 2003.
32. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006;55:749-53. (Pubitemid 43764536)
33. DIRUM. Database of Instruments for Resource Use Measurement. http://www.dirum.org/ (accessed 18 Feb 2014).
34. Curtis L. Unit costs of health and social care. Canterbury: University of Kent, 2012.
35. Briggs A, Clark T, Wolstenholme J, et al. Missing... presumed at random: cost-analysis of incomplete data. Health Econ 2003;12:377-92. (Pubitemid 36603549)
36. Cox DR. Regression models and life-tables. J R Stat Soc B 1972;34:187-220.
37. Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making 1998;18(2 Suppl):S68-80. (Pubitemid 28175944)
38. Efron B, Tibshirani R. An introduction to the bootstrap. NewYork: Chapman and Hall, 1993.
39. Punekar YS, Hawkins N. Cost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitis. Eur J Health Econ 2010;11:67-76.
40. Drummond MF, Sculpher MJ, Torance GW, et al. Methods for the economic evaluation of health care programmes. 3rd edn. Oxford: Oxford University Press, 2005.
41. Rapport F. Summative analysis: a qualitative method for social science and health research. Int J Qual Methods 2010;9:270-90.
42. Ryan GW, Bernard HR. Data analysis and management methods. In: Denzin NK, Lincoln US, eds. Handbook of qualitative research. 2nd edn. Newbury Park, CA: Sage, 2000:769-902.
43. Thorne K, Jezembek GS, Cheung WY, et al. MATRICS: a method for aggregating the reporting of interventions in complex studies. Trials 2011;12(Suppl 1):A147.
44. Department of Health. Research governance framework for health and social care. 2nd edn. London, 2005.
45. Scottish Executive Health Department. Research governance framework for health and community care. 2006.
46. Wales Office for Research and Development for Health and Social Care. Research governance framework. 2nd edn., 2009.
47. European Parliament and Council. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. http://eur-lex.europa.eu/LexUriServ/ LexUriServ.do?uri=OJ:L:2001:121:0034:0044:en:PDF (accessed 18 Feb 2014).
48. Medicines for Human Use (Clinical Trials) Regulations 2004. Medicines for human use (clinical trials) regulations 2004. London: HMSO, 2004.
49. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c869.